Lumiracoxib is effective in the treatment of osteoarthritis of the knee: A 13 week, randomised, double blind study versus placebo and celecoxib

Annals of the Rheumatic Diseases

Volumn 63, Issue 11, 2004, Pages 1419-1426

  Tannenbaum, H ^a   Berenbaum, F ^b   Reginster, J Y ^c   Zacher, J ^d   Robinson, J ^e   Poor, G ^f   Bliddal, H ^g   Uebelhart, D ^h   Adami, S ⁱ   Navarro, F ^j   Lee, A ^k   Moore, A ^k   Gimona, A ^k  

^a Rheumatic Disease Centre of Montreal   (Canada)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d HELIOS Klinikum Berlin   (Germany)

^e Crosby Clinical Research Centre   (United Kingdom)

^f Orszagas Reumatalagiai/Fiziaterapias   (Hungary)

^g FREDERIKSBERG HOSPITAL   (Denmark)

^h UNIVERSITY OF ZURICH   (Switzerland)

ⁱ Centra di Osteoporosis   (Italy)

^j HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; GASTROINTESTINAL SYMPTOM; GLOBAL ASSESSMENT OF DISEASE ACTIVITY SCORE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; OSTEOARTHRITIS PAIN INTENSITY SCORE; OUTCOMES RESEARCH; PAIN ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; STATISTICAL ANALYSIS; THORAX PAIN; VISUAL ANALOG SCALE; WOMAC PAIN SUBSCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOENZYMES; LOGISTIC MODELS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; ORGANIC CHEMICALS; OSTEOARTHRITIS, KNEE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 4344569331     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.015974     Document Type: Article

References (39)

1. Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002;41(suppl 1):3-6.
2. ACR. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905-15.
3. Dougados M. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. Clin Exp Rheumatol 2001;19(suppl 25):S9-14.
4. Moskowitz RW. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a United States viewpoint. Clin Exp Rheumatol 2001;19(suppl 25):S3-8.
5. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001;110(suppl 3A):20-7S.
6. Paulus HE. FDA arthritis advisory committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved. Arthritis Rheum 1988;31:1450-1.
7. Moore RA. The hidden costs of arthritis treatment and the cost of a new therapy-the burden of non-steroidal anti-inflammatory drug gastropathy. Rheumatology (Oxford) 2002;41(suppl 1):7-15.
8. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2000;4:CD002296.
9. Vane J, Botting R. Inflammation and the mechanism of action of antiinflammatory drugs. FASEB J 1987;1:89-96.
10. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
11. Marshall PJ, Berry JC, Wasvary J, Van Duzer J, Scott G, Rordorf C, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002;61(suppl I):259 (abstr SAT0013).
12. Atherton CT, Jones JI, McKaig BC, Bebb J, Cunliffe R, Burdsall J, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004;2:113-20.
13. Scott G, Rordorf C, Milosavljev S, Chase W, Fleischmann R, Kivitz A. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. In: Tulunay FC, Orme M, eds. European collaboration: towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer, 2003:124(abstr P-197).
14. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos 2004;32:566-71.
15. Weaver ML, Flood DJ, Kimble EF, Fujimoto RA. Lumiracoxib demonstrates preferential distribution to inflamed tissue in the rat following a single oral dose: an effect not seen with other cyclooxygenase-2 inhibitors. Ann Rheum Dis 2003;62(suppl I):378 (abstr AB0044).
16. Dawson J, Jagher B, Toscano KT, Fujimoto RA, Quadros E. Lumiracoxib shows rapid distribution to inflamed sites in a rat tissue chamber model compared with rofecoxib and celecoxib. Ann Rheum Dis 2003;62(suppl I): 377 (abstr AB0042).
17. Scott G, Rordorf C, Reynolds C, Kalbag J, Looby M, Milosavljev S, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-78.
18. Scott G, Rordorf C, Blood P, Branson J, Milosavljev S, Greig G. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002;61:242(suppl I):242 (abstr FRI0300).
19. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. In: Tulunay FC, Orme M, eds. European collaboration: towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer, 2003:124(abstr P-199).
20. Scott G, Branson J, Milosavljev S, Rordorf C, Haraoui B, Ouellet J-P, et al. Lumiracoxib demonstrates dose-proportional and time-independent pharmacokinetics in patients with osteoarthritis of the knee. Ann Rheum Dis 2003;62(suppl I):267 (abstr FRI0235).
21. Schnitzer TJ, Geusens P, Hasler P, Patel SK, Poor G, Senftleber I, et al. Efficacy and safety of COX189 in osteoarthritis: a multi-national study. Arthritis Rheum 2000;43(suppl 9):1616 (abstr S336).
22. Benevolenskaya L, Tüzün S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003;62(suppl I):270 (abstr FRI0246).
23. Grifka J, Zacher J, Brown J, Seriolo B, Lee A, Moore A, et al. Lumiracoxib is effective and well tolerated in patients with osteoarthritis of the hand: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003;62(suppl I):263 (abstr FRI0222).
24. Hawkey CJ, and the PUCCINI (Prevention of Ulcers with COX189 Compared with Ibuprofen In NSAID Investigation) study group. Reduced cumulative incidence of gastroduodenal ulcers with two doses of a new coxib, COX189 compared with standard therapeutic doses of ibuprofen in osteoarthritis patients. Gastroenterology 2002;122(suppl 1):A-345 (abstr M1732).
25. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey CJ. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004;19:1189-98.
26. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
27. Bellamy N, Buchanan WW, Goldsmith, CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
28. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
29. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. A placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001;30:11-18.
30. Celecoxib (Celebrex®) Package Insert. Pharmacia Pfizer, 2000.
31. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cycloaxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
32. Falissard B, Ravaud P, Tubach F, Logeart I, Baron G, Dougados M. Determination of a minimal clinically meaningful difference in the WOMAC physical function score: application of a new concept, the MDP75. Ann Rheum Dis 2003;62(suppl I):267 (abstr FR10236).
33. Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000;95:1681-90.
34. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
35. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
36. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000;284:1247-55.
37. Juni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 2002;324:1287-8.
38. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: a systematic review of randomised controlled trials. BMJ 2002;325:619-26.
39. Rordorf C, Kellett N, Mair S, Ford M, Milosavljev S, Branson J, et al. Gastroduodenal tolerability of lumiracoxib versus placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003;18:533-41.